- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2017–2022 · grant · PCRP
Regulation of the Androgen Receptor Splice Variant, AR-V7, in Castration-Resistant Prostate Cancer
Srinivas Viswanathan · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2017–2022 · research · R01
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Unlocking the Potential of PI3K Inhibition in CLL
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · fellowship · F30
Dissecting and targetting HDMX-medicated chemoresistance in human cancer
Ann Morgan Cathcart · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2024 · grant · PCRP
Temporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer
Himisha Beltran · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2017–2020 · cooperative agreement · U01
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2028 · cooperative agreement · U24
Cancer Immune Monitoring and Analysis Center
Frank S Hodi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
Lili Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · fellowship · F30
Dissecting and targetting HDMX-medicated chemoresistance in human cancer
Ann Morgan Cathcart · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · research · R01
Disseminating an Evidence-Based Tobacco Control intervention for School Teachers in India
Glorian C Sorensen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · cooperative agreement · U01
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
William C. Hahn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care
Joanne Wolfe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · research · R33
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes
G. Mike Makrigiorgos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017 · grant · Lung Cancer Research Foundation Annual Grant Program
2017 – Lung Cancer Research Foundation Annual Grant Program – Dana-Farber Cancer Institute – Alison Taylor, PhD
Alison Taylor · Dana-Farber Cancer Institute · funded by Lung Cancer Research Foundation
2017–2022 · research · R01
Prevention of HIV-1 transmission by small-molecule CD4-mimetic entry inhibitors
Navid Madani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biology
Kimmie Ng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · fellowship · F32
Cross-species identification and validation of synthetic lethal relationships with VHL inactivation
Hilary Elaine Nicholson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · career development · K08
Improving Hospice Use for Patients with Blood Cancers
Oreofe Olukemi Odejide · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R50
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinases
Eunyoung Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Dissecting mechanisms of immunotherapy resistance in melanoma patients
Benjamin Izar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · research · R01
GENOMIC INSIGHTS AND THERAPEUTIC TARGETING OF ORAL CANCER TUMOR INITIATING CELLS
Ravindra Uppaluri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · fellowship · F32
CDX2 regulation of anti-repressive enhancers in intestinal epithelium
Madhurima Saxena · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2020 · fellowship · F32
CDX2 regulation of anti-repressive enhancers in intestinal epithelium
Madhurima Saxena · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · research · R33
Reducing viral reservoirs by opening HIV-1 Env to antibody attack
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R25
Summer Program to Advance Research Careers (SPARC)
Edward J Benz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2021 · research · R01
Metabolic and Bioenergetic Control in Mitochondrial Diseases
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2023 · research · R01
Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R50
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinases
Eunyoung Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2021 · research · R01
A systems biology approach for dissecting enhancer hierarchy
Guo-Cheng Yuan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
Lili Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Overcoming resistance in BCR-ABL-rearranged acute lymphoblastic leukemia
Mark A. Murakami · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R50
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinases
Eunyoung Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2027 · research · R01
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2019 · career development · K99
Investigating the role of KLF5 genomic alterations in tumorigenesis
Xiaoyang Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · cooperative agreement · UG1
Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency
Jerome Ritz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · research · R01
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
Lili Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2022 · career development · K08
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2017–2021 · research · R01
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
